Browse Articles
Discover research articles across all indexed journals
Tunable Electron Correlation in Epitaxial 1T‐TaS<sub>2</sub> Spirals (Adv. Mater. 6/2025)
Cancer Immunotherapy Trials Network 12: Pembrolizumab in HIV-Associated Kaposi Sarcoma
PURPOSE Cancer Immunotherapy Trials Network 12 demonstrated safety of pembrolizumab in treating advanced cancer in people with HIV. Here, we report results of the Kaposi sarcoma (KS) cohort. METHODS In this multicenter phase I trial, we enrolled participants with HIV-associated KS on antiretroviral therapy with CD4 + ≥50 cells/μL and HIV plasma RNA <200 copies/mL. Pembrolizumab 200 mg intravenously was administered once every 3 weeks for up to 35 cycles. The primary end point was safety, and the secondary end point was KS response by modified AIDS Clinical Trials Group Criteria. RESULTS Thirty-two cisgender men enrolled with baseline median CD4 + T-cell count of 274 cells/µL. All but nine participants had received previous systemic KS therapy. Participants received a median of 11 cycles of pembrolizumab (range, 1-35). Sixty-six percent had grade ≥1 treatment-emergent adverse events, including one death from polyclonal KS herpesvirus–related B-cell lymphoproliferation. Thirty-one percent had ≥one immune-mediated AEs (imAEs) with 25% requiring systemic steroids. In 29 participants with evaluable KS, the overall response rate (ORR) was 62.1% (95% CI, 42.3 to 79.3) and did not differ by CD4 + T-cell count. ORR in the eight participants with evaluable disease without previous KS therapy was 87.5% (95% CI, 47.3 to 99.7). Median duration of response (DOR) was not reached, and the Kaplan-Meier estimate of DOR of ≥12 months was 92.3% (95% CI, 56.6 to 98.8). Median progression-free survival was 28.2 months (95% CI, 4.2 to noncalculable). CONCLUSION Pembrolizumab yielded a high rate of durable responses in HIV-associated KS. imAEs were successfully managed with standard guidelines.
Retrospective study of fluoropyrimidine chemotherapy dosing and toxicity in patients with screen-detected deleterious <i>DPYD</i> gene variants.
293 Background: Fluoropyrimidine chemotherapy agents are commonly used to treat solid tumors. Fluoropyrimidines are degraded by the enzyme dihydropyridine dehydrogenase (DPD), encoded by the DPYD gene. Deleterious variants in DPYD leads to functional DPD deficiency and increased toxicity risk. Methods: We conducted a retrospective study of patients with screen-detected deleterious DPYD variants who were treated with fluoropyrimidine chemotherapy between 01/01/15-04/15/23. Outcomes of interest were initial fluoropyrimidine dosing, dose adjustments (cycles 2-6), and early toxicities. Results: We identified 12 patients with heterozygous DPYD variants, including *2A (n=5), c.2846A>T (3), c.1129-5923C>G (2) and *13 (2). Initial chemotherapy regimens included FOLFOX (7), mFOLFIRINOX (3) and CAPEOX (1). Of 11 patients receiving FOLFOX/mFOLFIRINOX, nine began treatment with a 50-60% reduction of the 5-FU infusion dose, one received a 25% reduction, and one received a standard dose (due to treatment initiation prior to return of the genotype result). Seven patients tolerated the initial 5-FU infusion dose without further dose reductions, including three who tolerated limited dose-escalation. Four patients required further dose reduction from the cycle 1 dose, due to toxicity. The patient who received a standard 5-FU infusion dose in cycle 1 experienced grade 3 toxicity, but tolerated subsequent treatment after 50% dose reduction. The patient treated with CAPEOX tolerated 4 planned cycles with a 50% capecitabine dose reduction. Conclusions: Most patients who screened positive for deleterious DPYD gene variants tolerated fluoropyrimidine chemotherapy with a 50% dose reduction. However, 3 of 12 patients experienced toxicity requiring treatment discontinuation or dose reduction to less than 50% of the standard 5-FU dose.
A systematic literature review of studies assessing first-line (1L) treatments in patients with advanced, grade 2/3 (G2/G3) gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
663 Background: There is no universally accepted standard of care for newly diagnosed patients with G2/G3 advanced GEP-NETs. The phase 3 NETTER-2 trial showed that [ 177 Lu]Lu-DOTA-TATE plus long-acting octreotide demonstrated a significant improvement in progression-free survival (PFS) vs. high-dose long-acting octreotide alone in this patient population. We conducted a comprehensive review of the published literature to summarize the available evidence on other 1L treatments assessed in advanced, well-differentiated, G2/G3 GEP-NETs. Methods: Embase, MEDLINE, and CENTRAL were systematically searched (until Jan 2024) to identify relevant clinical trials and observational studies assessing 1L systemic therapies among adults with advanced, well-differentiated, G2/G3 GEP-NETs. Key conferences from the past three years were also reviewed. Comparators of interest included somatostatin analogues (SSAs; octreotide and lanreotide), targeted therapies (sunitinib and everolimus), and chemotherapies (CAPTEM, STZ+5-FU, FOLFIRI, and platinum-based therapies). Studies with mixed patient populations were also included if ≥80% of the study participants matched the eligibility criteria. The 2022 WHO classification system was applied in studies with available Ki-67 index data but lacking grade information. Results: A total of 31 studies met the review eligibility criteria (three randomized controlled trials, one open-label extension study, three single-arm trials, and 24 observational studies). None of the included studies entirely matched the NETTER-2 population but provided data only for specific sub-populations. The included studies were categorized either by overall GEP-NET (n=16) or pancreatic-NET only population (n=15) with no study exclusively assessing gastrointestinal-NET patients. Majority of the comparator studies assessed chemotherapies (n=14), followed by SSAs (n=10), targeted therapies (n=3), a combination of targeted therapy and chemotherapy (n=1), and mixed treatments (n=2). Heterogeneity was also observed in terms of patient characteristics (data reported only in 12 studies), sample size (<50 patients in 20 studies), and disease grade (G2/G3: nine studies, G2 only: 12 studies, and G3 only: 10 studies). Grading was derived using Ki-67 index in two studies. Majority of the studies reported PFS data (n=22), with nine studies providing data for both PFS and overall survival (OS); Kaplan-Meier curves for PFS and OS were reported for only 13 and four studies, respectively. Conclusions: This systematic literature review highlights a substantial evidence gap and an unmet need in 1L treatment of G2/G3 GEP-NETs. Robust quantitative comparison of NETTER-2 data with published evidence on other 1L treatments was largely restricted by low sample sizes and the aforementioned heterogeneity.
Designing Silk Biomaterials toward Better Future Healthcare: The Development and Application of Silk‐Based Implantable Electronic Devices in Clinical Diagnosis and Therapy (Adv. Mater. 8/2025)
Designing Current Collectors to Stabilize Li Metal Anodes
Abstract Rechargeable batteries employing Li metal anodes have gained increasing attention due to their high energy density. Nevertheless, low stability and reversibility of Li metal anodes severely impeded their practical applications. Designing current collectors (CCs) with reasonable structure and composition is an efficient approach to stabilizing the Li metal anodes. However, an in‐depth comprehensive understanding about the design principles and modification strategies of CCs for realizing stable Li metal anodes is still lacking. Herein, a critical review focusing on the rational design of CCs for Li metal anodes is summarized. First, the requirements for CCs in Li metal anodes are elucidated to clarify the design objectives of CCs. Then, the modification strategies of CCs including lithiophilic site modification, 3D architecture construction, protective layer modification, and crystalline plane engineering, as well as the corresponding principles are highlighted. On this basis, the recent progress in the development of CCs for Li metal anodes is discussed. Finally, future directions are suggested to focus on developing operando monitoring technology, and designing the CCs and cells under practical conditions close to the requirements of commercial applications. This review will spur more insightful researches toward advanced CCs, and promote their commercialization.
Patterns of radiological progression in participants (pts) with embolization-eligible hepatocellular carcinoma (HCC) treated with durvalumab (D) + bevacizumab (B) + transarterial chemoembolization (TACE) and placebos + TACE: EMERALD-1 post hoc analysis.
574 Background: EMERALD-1 (NCT03778957) met its primary endpoint, demonstrating improved progression-free survival (PFS) in pts with locoregional HCC treated with D + B + TACE versus placebos (PBO) + TACE (stratified Cox proportional hazards hazard ratio [HR], 0.77; 95% confidence interval [CI], 0.61–0.98 [Lencioni R, et al. J Clin Oncol 2024;42(suppl 3). Abs LBA432]). This post hoc analysis assessed outcomes by radiological progression pattern in pts treated with D + B + TACE or PBO + TACE. Methods: Pts included in this analysis received D (1500 mg) or PBO for D (Q4W) in combination with conventional (c)- or drug-eluting bead (DEB)-TACE (investigator choice, 1–4 TACE procedures within 16 weeks). Subsequently, pts received D (1120 mg) + B (15 mg/kg), or PBO for D + B (Q3W). This study analyzed radiological progression patterns at the time of first progressive disease (PD) as assessed by the investigator per modified Response Evaluation Criteria in Solid Tumors. A new lesion was classified as a new intrahepatic lesion (NIH) or new extrahepatic lesion (NEH); tumor growth of existing intrahepatic lesions (increase of ≥20% of an existing target lesion with at least >5 mm absolute increase or unequivocal PD with a non-target lesion) was classified as intrahepatic growth (IHG; categories were not mutually exclusive). Efficacy was assessed by time to progression (TTP). Results: In the D + B + TACE arm, 53.9% of pts had PD, and in the PBO + TACE arm 79.0% of pts had PD. The most common pattern of disease progression across both treatment arms was NIH, occurring in 73 (35.8%) and 107 (52.2%) pts in the D + B + TACE and PBO + TACE arms, respectively, with 31 (15.2%) and 34 (16.6%) pts exhibiting IHG, and 24 (11.8%) and 39 (19.0%) pts exhibiting NEH, respectively. Improved TTP was observed in pts treated with D + B + TACE versus PBO + TACE, regardless of progression pattern (Table). Conclusions: Overall, the rate of progression was lower with D + B + TACE compared with PBO + TACE. The pattern of disease progression observed with D + B + TACE and PBO + TACE was similar, with NIH the most common pattern of progression in both treatment arms. Consistent benefit in TTP was observed with D + B + TACE versus PBO + TACE, regardless of progression pattern. Clinical trial information: NCT03778957 . NIH IHG NEH D + B + TACE (n=73) PBO + TACE (n=107) D + B + TACE (n=31) PBO + TACE (n=34) D + B + TACE (n=24) PBO + TACE (n=39) Median (95% CI) TTP, months 13.7 (10.8–16.5) 8.8 (7.0–10.9) 5.1 (3.0–9.0) 4.3 (2.9–4.8) 6.7 (2.8–16.6) 4.6 (2.9–6.8) HR (95% CI)* 0.78 (0.57–1.07) 0.61 (0.36–1.03) 0.66 (0.36–1.15) *HR and CI were estimated using a Cox proportional hazards model, the CI was calculated using a profile likelihood approach.
Phase II study of neoadjuvant NALIRIFOX followed by chemoradiation with paclitaxel and carboplatin in locally advanced gastroesophageal cancer.
452 Background: We performed a single-arm phase II study of neoadjuvant NALIRIFOX and chemoradiation (CRT) with concurrent carboplatin/taxol (C/T) followed by surgery in patients with locally advanced gastroesophageal (GE) cancer. Methods: Patients were enrolled on an NCI sponsored, prospective, single arm study (NCT04656041). Key eligibility criteria included: histologically confirmed T3/4 or lymph node (LN) positive GE junction or esophageal cancer, ECOG PS ≤1, age 18+, and life expectancy > 3 months. Exclusion criteria included: metastatic disease, prior chemotherapy or RT, or prior targeted therapy for diagnosis. Extensive LN disease beyond the surgical field (supraclavicular or para-aortic) was permitted if deemed feasible to be encompassed within a RT field. Laparoscopy was not required. Pts were treated with neoadjuvant NALIRIFOX x 4-8 cycles pending patient tolerance and physician discretion, restaging, CRT (50.4 Gy in 28 fractions) with concurrent C/T, restaging, followed by surgical resection. Dose reductions were at discretion of the treating physician. The primary study endpoint was the pathologic complete response rate following neoadjuvant treatment with NALIRIFOX and CRT with concurrent C/T. Major pathologic response (mPR) was defined as Tumor Regression Grade 0 and 1. Secondary endpoints included: 1) acute toxicity; 2) clinical response per RECIST criteria; 3) PFS and 4) OS. Results: From June 2021 to October 2023, 40 patients were enrolled. Median age was 64 (range: 47-82), and 31 patients were male (78%). All patients started NALIRIFOX, and the median number of NALIRIFOX received was 5 (range: 1-8). Reasons for discontinuation of NALIRIFOX were: physician discretion (n=29), subject withdrew from treatment (n=2), progressive disease (n=1), death (n=1). Rates of grade 3+ toxicity for overall, gastrointestinal, and hematologic attributed to NALIRIFOX were 55%, 35%, and 13% respectively. 35 patients started chemoRT (88%) and 33 patients completed chemoRT (83%). Rates of grade 3+ toxicity for overall, gastrointestinal, and hematologic attributed to chemoRT were 86%, 11%, and 9% respectively. Of 33 who completed chemoRT, two patients declined surgery (including 1 with clinical CR), and 31 (78%) patients went for surgical exploration. No patients were found with intraoperative metastases. Therefore, 31 (78%) patients underwent surgical resection. In total, 9 patients had pCR (29% in resected cohort, 23% in ITT cohort) and 15 had a major PR (48% in resected cohort, 38% in ITT cohort). In total, 10 (25% in ITT) patients had pCR or clinically CR at 1 year. Conclusions: Neoadjuvant NALIRIFOX followed by CRT is feasible with acceptable rates of treatment completion and grade 3+ toxicity. In our phase II trial, the rate of pCR is promising and further studies incorporating this regimen should be considered. Clinical trial information: NCT04656041 .
Assessing socioeconomic disparities and the likelihood of multimodal treatment utilization in patients with pancreatic cancer using SEER Medicare data.
677 Background: Optimal treatment for pancreatic cancer necessitates multimodal therapies combining surgery, chemotherapy, and radiation. Socioeconomic determinants of health may influence access to these treatments, leading to disparities in outcomes. This study examines the association between socioeconomic status (SES) and the likelihood of receiving multimodal treatment among pancreatic cancer patients using SEER Medicare data. Methods: Our study population consists of elderly persons diagnosed with pancreatic cancer from the 2008–2017 SEER-Medicare dataset. A multinomial logistic regression controlling for sociodemographic characteristics, cancer stage, comorbidities, geographic region, and ecological measures of urbanicity and SES was used to assess the likelihood of receiving one of three mutually exclusive treatment categories: no treatment, one modality (surgery, chemotherapy, or radiotherapy), or multiple modalities (different combinations of surgery, chemotherapy, and radiotherapy), with multiple modalities as the reference group. Survival analysis was conducted using Kaplan-Meier curves (KMC) and Cox proportional hazards (CPH) models. Results: Adjusted analyses showed that among stages 0–3 patients, living in areas with a high percentage of individuals without a high school education (non-HS) was associated with increased odds of receiving no treatment (OR = 1.26, p < 0.01) and one modality (OR = 1.20, p < 0.01) versus multiple modalities. Low median household income was linked to higher odds of no treatment (OR = 1.30, p < 0.01) and one modality (OR = 1.16, p < 0.05). This pattern persisted in stage 4 patients, where high non-HS percentage increased odds of no treatment (OR = 1.38, p < 0.01), and low median income was associated with higher odds of no treatment (OR = 1.25, p < 0.05). Non-Hispanic Black patients had higher odds of receiving no treatment in both stages 0–3 (OR = 1.26, p < 0.05) and stage 4 (OR = 1.91, p < 0.01) compared to Non-Hispanic Whites. Being married was associated with reduced odds of receiving no treatment for stages 0–3 (OR = 0.53, p < 0.01) and stage 4 (OR = 0.55, p < 0.01). Lower SES and being Non-Hispanic Black are associated with decreased likelihood of receiving multimodal treatment across all stages. Patients receiving multimodal therapies demonstrated improved survival on our KMC analysis, and CPH models indicated lower mortality for those receiving multiple modalities. Conclusions: Socioeconomic disparities significantly influence multimodal treatment utilization in pancreatic cancer. Lower SES indicators—high non-HS percentages, low median income—and being Non-Hispanic Black are associated with decreased use of multimodal therapies and poorer survival. Addressing these disparities is essential to ensure equitable access to optimal treatments and improve survival rates.
Highly Stretchable 3D Microelectrode Array for Noninvasive Functional Evaluation of Cardiac Spheroids and Midbrain Organoids (Adv. Mater. 6/2025)
High‐Throughput Screening and General Synthesis Strategy of Single‐Atom Nanozymes for Oral Squamous Cell Carcinoma Therapy
AbstractSingle‐atom nanozymes (SAzymes), with their superior enzyme‐like catalytic activity, have emerged as promising candidates for oncology therapeutics. The well‐defined structures of SAzymes make them well predictable by experiences and theoretical calculation. However, the effects of metal center species and coordination environments on enzyme‐like activity are variable, and screening catalytic activity by artificial experiments is challenging. High‐throughput screening can rapidly select the activity center structures of SAzymes with optimal enzyme‐like activity, thus their better application in tumor therapy is highly desirable. Herein, a “high‐throughput screening‐SAzymes structures” system is established for efficient oncology drug preparation by density functional theory for oxidase‐like processes and screened the differences brought about by different metals and coordination environments. Through this screening process, SAzymes with transition metals (Mn, Fe, Co, Ni) as active centers are synthesized and then tested the multi‐enzyme activities. It is found that the SAzyme with Co as the active metal center exhibited the best oxidase‐like activity, and the system further showed good anti‐oral squamous cell carcinoma properties both in vitro and in vivo. This study opens up a new avenue for the rational design of SAzymes in oral cancer therapy by combining computational screening and experimental validation.
Development and regulatory approval of a new systemic targeted therapy for advanced hepatocellular carcinoma.
613 Background: There are no commercially available devices for the treatment of patients with advanced hepatocellular carcinoma who have failed 1st line and 2nd line therapy. We have identified tumor-specific modulation frequencies in patients with advanced hepatocellular carcinoma. We exposed patients to radiofrequency electromagnetic fields, which are amplitude-modulated from 0.1 Hz to 100 kHz and measured changes in pulse pressure. Frequencies eliciting measurable changes in pulse pressure were selected as tumor-specific frequencies. Methods: Treatment is administered to patients with advanced hepatocellular carcinoma by means of a battery-operated portable device emitting 27 MHz radiofrequency electromagnetic fields, which are amplitude-modulated at hepatocellular carcinoma frequencies. The device is connected to a coaxial cable ending with a spoon-shaped antenna placed on the anterior part of the patient's tongue during treatment. Treatment is administered three times a day for one hour. Results: A total of 69 patients with advanced hepatocellular carcinoma received treatment with the TheraBionic device until progression or death. The median overall survival of patients who received treatment with the TheraBionic device after failing 1st line and 2nd line therapy was 9.15 (95% CI 1.6-34.8) months and the median overall survival of Child-Pugh A patients was 9.5 months, which are comparatively longer than the 7.8 months pooled estimated medians of the placebo arms of 11 randomized 1st line and 2nd line placebo-controlled studies assessing the safety and efficacy of new agents for the treatment of Child-Pugh A advanced HCC (Llovet, Montal et al., J Hepatol 2019). We also analyzed the survival of patients who had received two lines of systemic therapy and did not receive any additional cancer treatment while and after receiving treatment with the TheraBionic device. The median OS of these patients was 9.8 months and the median OS of the Child-Pugh A patients was 17.2 months, which are comparatively longer than the 7.74 months pooled estimated medians of the placebo arms of the above cited 11 randomized studies. To assess unknown device-related adverse events, we assessed patient reported symptoms using the same scale in the SHARP and Asian Pacific Sorafenib studies. The incidence of any grade adverse events among Child-Pugh A who received treatment with the TheraBionic device was not different from the Placebo group of the SHARP and Asian Pacific Sorafenib studies. There were no NCI Grade 2, 3 or 4 toxicities. One patient developed grade 1 mucositis and one patient developed grade 1 fatigue. Conclusions: The data presented here provide reasonable assurance of safety and probable benefit in patients with advanced hepatocellular carcinoma who have failed 1st line and 2nd line therapy: https://www.fda.gov/medical-devices/recently-approved-devices/therabionic-p1-h220001 .
Alteration of gut microbiota in patients with advanced hepatocellular carcinoma.
641 Background: Hepatocellular carcinoma (HCC) is the most common primary liver cancer and the third leading cause of cancer-related death worldwide. Despite advancements in treatment, such as novel combinations of immunotherapy and targeted therapy or dual immunotherapy, the prognosis remains poor due to a lack of predictive biomarkers for treatment response. Gut microbiota alterations have been proposed as both potential diagnostic biomarker and predictive biomarker. However, data in this field are not well-established and are mostly derived from studies conducted in China and Western countries, which may not fully reflect the situation in Thailand. Methods: Fecal samples were collected from pre-treated advanced HCC patients who visited medical oncology outpatient clinic at Srinagarind hospital, Khon Kaen University (HCC group = 27) and analyzed using 16S rRNA sequencing of gut microbiota. Additional sequenced data from a healthy population (Control group = 31) who had no underlying disease and had normal liver ultrasonography were retrieved from a previous study conducted by Khon Kaen University (Cholangiocarcinoma Screening and Care Program, CASCAP). The datasets were compared using the Wilcoxon rank-sum test to analyze the alteration of gut microbiota between HCC group and control group. Results: The HCC group exhibited significantly lower biodiversity index (p< 0.001) than control group in terms of richness, Shannon diversity index and Simpson’s index. The HCC group had significantly higher relative abundance of the phylum Proteobacteria (p< 0.001), Firmicutes (p< 0.001) and a lower abundance of the phylum Actinobacteria (p< 0.001) compared to the control group. Additionally, the HCC group had significantly higher relative abundance of Stenotrophomonas, Granulicatella, Ruminococcus, Blautia, Phascolarctobacterium, Butyricoccus, Streptococcus, Escherichia-Shigella, Flavonifractor, Haemophilus and Lachnospira at the genus level. Further analysis of relative abundance of gut microbiota at the genus level and clinical prognostic parameters showed positive correlation between Streptococcus and 6-month survival status. Conclusions: Gut microbiota profile in patients with advanced HCC was significantly altered from healthy control group. This could be the evidence of microbial dysbiosis and may potentially be biomarker for prognosis.
Colorectal cancer legal and administrative burden support (COLLABS): A pilot clinical trial.
TPS307 Background: Patients with colorectal cancer often have health-related social needs (e.g. food insecurity, housing instability, employment loss). Failure to adequately address these is associated with financial hardship, worse quality-of-life, psychosocial distress, lower rates of treatment receipt, and worse survival. Cancer clinical care teams often lack the resources, knowledge, and processes to resolve these issues, many of which are actually legal in nature. Engagement with legal teams—medical-legal partnerships—can screen for, prevent, and resolve health-related social needs, as well as address related legal issues such as insurance denials, employment rights and protections, disability benefits, debt management, and estate planning. Cancer Legal Care (CLC) is a nonprofit providing free legal services to persons affected by cancer in MN. Past CLC clients have indicated a preference for proactive connection to CLC to prevent crises and overcome barriers to access such as concerns regarding perceived costs of legal services. Methods: This is a single-arm, pilot study to evaluate the feasibility, acceptability, and preliminary efficacy of proactive and free legal care support for patients with colorectal cancer at the University of Minnesota. The enrollment goal is 20 patients and the trial duration is 6 months. Inclusion criteria include English-speaking adults with advanced stage colorectal cancer and estimated life expectancy of >6 months. There is no requirement for baseline health-related social need(s) or time from diagnosis. After participants complete baseline surveys, we will connect them to a CLC attorney for an initial “legal care checkup”— the timing and method of connection (in-person, video visit, or phone call) is based on patient preference. Patients can bring up self-identified or active issues themselves, while CLC will also screen for needs. CLC will provide any required legal services and engage with the cancer care team as needed. CLC will follow-up with participants at 3 and 6 months, though services may continue after the study period off trial. Participants will complete surveys at baseline, 3 months, and 6 months. Surveys will assess patient-reported outcomes on financial toxicity, quality-of-life, comfort levels with accessing cancer care, status of health-related social and legal needs, perceived stress, life mastery and engagement, relationship with CLC contact, and acceptability of the intervention. The primary outcomes are feasibility (rates of initial engagement, continued engagement, and intervention completion; feasible if >50% on each metric) and acceptability. We will conduct exit qualitative interviews. We will collect sociodemographics, rates of treatment adherence/ completion, legal services provided, outcome of legal issues, and monetary savings or recovery for patients. Enrollment opened August 2024 and we have enrolled 15/20 participants. Clinical trial information: NCT06475664 .
Polymorphing Hydrogels Regulated by Photo‐reactive DNA Cross‐links (Adv. Mater. 5/2025)
Dual‐Phase Ligand Engineering Enables 18.21% FAPbI<sub>3</sub> Quantum Dot Solar Cells
AbstractFormamidinium lead triiodide (FAPbI3) perovskite quantum dot (PQD) are promising candidate for high‐performing quantum dot photovoltaic due to its narrow bandgap, high ambient stability, and long carrier lifetime. However, the carrier transport blockage and nonradiative recombination loss, originating from the high‐dielectric ligands and defects/trap states on the FAPbI3 PQD surface, significantly limit the efficiency and stability of its photovoltaic performance. In this work, through exploring dual‐site molecular ligands, namely 2‐thiophenemethylammonium iodide (2‐TM) and 2‐thiopheneethylammonium iodide (2‐TE), a dual‐phase synergistic ligand exchange (DSLE) protocol consisting of both solution‐phase and solid‐state ligand engineering is demonstrated. The DSLE strategy effectively replaces the native long insulating ligands and simultaneously passivate surface defects in hybrid FAPbI3 PQDs, leading to enhanced electronic coupling for efficient charge transport. Consequently, the FAPbI3 PQD solar cell based on DSLE strategy achieves a notable enhanced efficiency from 15.43% to 17.79% (2‐TM) and 18.21% (2‐TE), respectively. Besides, both 2‐TM and 2‐TE engineered devices exhibit enhanced stability, maintaining over 80% of its initial efficiency after aging in ambient environment (20–30% humidity, 25 °C) for over 1400 h. It believes these findings will provide a new protocol to precisely regulate the surface chemistry of hybrid PQDs toward high‐performance optoelectronic applications.
Concordance between PD-L1 assays 28-8 and SP263 and their respective scoring algorithms in procured upper gastrointestinal adenocarcinoma samples.
479 Background: PD-L1 is being studied as a predictive immunohistochemical (IHC) biomarker for gastroesophageal junction (GEJ), gastric (GC), and esophageal (EAC) adenocarcinomas, and anti-PD-(L)1 therapies are used to treat them. Here, we compare the VENTANA PD-L1 (SP263) IHC assay and its tumor area positivity (TAP) algorithm with the clinically validated Agilent PD-L1 IHC 28-8 pharmDX combined positive score (CPS) algorithm in GEJ, GC, and EAC samples. The degree of concordance between SP263 TAP ≥ 5% and 28-8 CPS ≥ 5 is important for interpreting real-world settings and emerging clinical trial data. Methods: GEJ, GC, and EAC tumor samples procured from company-sponsored clinical trials (NCT02545504, NCT02862535, NCT02864381) and external vendors with informed consent were analyzed 4 ways: SP263 TAP, SP263 CPS, 28-8 TAP, and 28-8 CPS. Readouts were evaluated by a single pathologist and were analyzed with Pearson correlation coefficients. Results: 286 patient samples were analyzed (GEJ, n = 106; GC, n = 88; EAC, n = 92). The agreement among the SP263 TAP ≥ 5% and 28-8 CPS ≥ 5 prevalence is shown in the Table. The overall correlation coefficient between 28-8 CPS and SP263 TAP was high ( R = 0.95; P < 2.2 × 10 −16 ). In addition, when applying the same scoring algorithm to both assays (SP263 TAP vs 28-8 TAP or SP263 CPS vs 28-8 CPS), the correlation coefficients remained high ( R = 0.97; P < 2.2 × 10 −16 ). When both algorithms were applied to the same IHC assay (SP263 TAP vs SP263 CPS or 28-8 TAP vs 28-8 CPS), the correlation coefficients were also high ( R = 0.98; P < 2.2 × 10 −16 ). Conclusions: In this controlled experiment the PD-L1 assays 28-8 and SP263 concordance was high. The scoring algorithms for GEJ, GC, and EAC samples were observed as highly correlated; minor differences were likely driven by the distinct PD-L1 monoclonal antibody clones utilized in the IHC assays. These data suggest that the 2 assays are comparable for evaluating PD-L1 expression at the TAP ≥ 5% and CPS ≥ 5 cutoffs. Clinical trial information: NCT02545504 , NCT02862535 , NCT02864381 . Concordance of SP263 TAP ≥ 5% with 28-8 CPS ≥ 5. Positive percentage agreement: 0.96Negative percentage agreement: 0.95Overall percentage agreement: 0.95 28-8 CPS ≥ 5: Positive 28-8 CPS ≥ 5: Negative SP263 TAP ≥ 5%: Positive 116 9 SP263 TAP ≥ 5%: Negative 5 156
Encorafenib and cetuximab with/without binimetinib therapies for patients with <i>BRAF</i> -mutated metastatic colorectal cancer with prognostic factors: The BEETS trial (JACCRO CC-18).
164 Background: BRAF inhibitor combination therapies, triplet (encorafenib, binimetinib and cetuximab) and doublet (encorafenib and cetuximab), have been approved for BRAF -mutated metastatic colorectal cancer (mCRC) in Japan. The treatment with triplet is recommended for patients (pts) with clinical prognostic factors according to the sub-group analysis of the BEACON CRC trial. However, it is unclear whether the treatment strategy is useful. We therefore conducted a study on the use of combination therapy with triplet or doublet based on observational study that accumulated real world data. Methods: The BEETS trial was a multicenter observational study to prospectively evaluate the efficacy and safety of BRAF inhibitor combination therapy as a 2nd- or 3rd-line treatment in pts with BRAF -mutated mCRC in clinical practice [UMIN000045530]. Two hundred pts were assigned to either triplet or doublet therapy based on the physician’s choice. The primary endpoint was overall survival (OS). The secondary endpoints included overall response rate (ORR), disease control rate, progression-free survival (PFS), and safety. The exploratory analysis was performed to evaluate the efficacy of triplet and doublet therapies in all pts and pts with clinical prognostic factors (PS1, 3 or more metastatic sites, elevated CRP value, or primary tumor present) using inverse probability weighting (IPW) analysis based on propensity scores to account for potential cofounding factors. Results: Among 203 pts enrolled from Oct 2021 to Nov 2023, 195 pts were evaluable (median age 67 years old, 52% male, ECOG PS 0/1/2 55%/39%/6%, no. of prior regimens 1/2 85%/15%, right-sided primary 61%, MSI-high 7%, triplet regimen 57%). Median OS was 13.2 months (95%CI 11.4-17.4) with 1y-survival rate of 53%, and median PFS was 4.9 months. Comparing the triplet and doublet using IPW, the median OS and PFS were comparable between the two treatments (triplet vs. doublet; 16.0 months vs. 13.6 months [HR 0.88, 95%CI 0.53-1.48] and 5.7 months vs. 4.8 months [HR 0.87, 95%CI 0.59-1.28]). In 139 pts with any prognostic factors, median OS and 1y-survival rate were 13.2 months vs. 9.6 months [HR 0.80, 95%CI 0.45-1.43] and 54% vs. 42%, median PFS and ORR were 5.3 months vs. 4.2 months [HR 0.75, 95%CI 0.48-1.19] and 34% vs. 42%, in the triplet vs. doublet therapy, respectively. Conclusions: Our study demonstrated that BRAF inhibitor doublet therapy is a reasonable treatment for BRAF -mutated mCRC. However, triplet therapy may be a clinically useful for pts with clinical prognostic factors. Clinical trial information: UMIN000045530 .
Neoadjuvant PD-1 blockade in mismatch repair-deficient or microsatellite instability-high, locally advanced and resectable colorectal cancer: A retrospective real-world analysis.
185 Background: Neoadjuvant PD-1 blockade therapy has shown encouraging efficacy in patients with mismatch repair- deficient (dMMR)/microsatellite instability-high (MSI-H) locally advanced colorectal cancer. However, data from the real-world setting are scarce. Methods: We retrospectively collected clinical data of patients with dMMR/MSI-H locally advanced colorectal cancer diagnosed between 2022-2024 that received neoadjuvant anti-PD-1 monotherapy at the First Affiliated Hospital of Zhengzhou University. Pathological complete response, clinical complete response, R0 resection rate, and safety were analyzed. All statistical analyses were conducted using SPSS Statistics, version 22.0. Results: A total of 45 patients were enrolled. As of the data cutoff (Sep 15, 2024), the median follow-up was 14.0 months (range: 4.0-31.4). The median age was 53 years (range: 29.0–78.0) and 25 (55.6%) of 45 patients were male. 32 (71.1%) patients had clinical stage III disease and 39 (86.7%) patients had colon cancer. A higher proportion of patients (53.3%) had clinical T4 stage. 37 patients underwent the surgery of whom 29(78.9%) had a pathological complete response. The R0 resection was 100%. The median treatment duration was 4 cycles (range: 2-10). Among the 18 patients who received equal to or less than 4 cycles, the pCR rate was 77.8%, while for the remaining 17 patients who had more than 4 cycles of treatment, the pCR rate was 84.2%. Eight other patients had a clinical complete response and chose the watch and wait strategy. Treatment-related adverse events ≥3-4grade were observed in 3 patients. All patients survived without any disease recurrence. Conclusions: In this retrospective analysis, anti-PD-1 monotherapy is effective and tolerable for patients with dMMR/MSI-H locally advanced colorectal cancer. This study shows that pCR rate increases is associated with a longer treatment cycles probably. Further analysis of larger real-world datasets with longer follow-up will be essential to validate these results.